• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Low levels of extraneous agents in vaccine starting materials.

作者信息

Rouby Jean-Claude

机构信息

AFSSA-Agency for Veterinary Medicinal Products, Javené, BP90203, F-35302 Fougères, France.

出版信息

Biologicals. 2010 May;38(3):354-7. doi: 10.1016/j.biologicals.2010.01.004. Epub 2010 Mar 26.

DOI:10.1016/j.biologicals.2010.01.004
PMID:20347331
Abstract

There are different ways to define the concept of 'low levels' of extraneous agents in vaccines and vaccine starting materials, based on the amount of extraneous agents as such, the sensitivity of the detection method and the probability approach linked to the sampling method. None of these approaches, however, is entirely satisfactory--a general definition of a 'low level' cannot be provided. Since the main point is the safety of medicinal products, the risk analysis approach to 'low level' contaminations can be considered as a way to overcome the above mentioned deadlock. But as too many variables impact the risk analysis, it cannot be properly performed either. In practice, seeds are tested to show freedom from extraneous agents, the other raw materials are inactivated through a validated method. However, there are technical and regulatory limits in both cases, and neither testing nor inactivation entirely guarantees freedom from extraneous agents. Despite this unsatisfactory situation, it should be acknowledged that no truly significant disease outbreak linked to an extraneous agent has been identified until today. Regulatory actions are mainly undertaken when a sanitary problem occurs. In the end, companies remain responsible for their products.

摘要

相似文献

1
Low levels of extraneous agents in vaccine starting materials.
Biologicals. 2010 May;38(3):354-7. doi: 10.1016/j.biologicals.2010.01.004. Epub 2010 Mar 26.
2
Tracing and control of raw materials sourcing for vaccine manufacturers.
Biologicals. 2010 May;38(3):352-3. doi: 10.1016/j.biologicals.2010.01.011. Epub 2010 Mar 23.
3
Extraneous agents testing for substrates of avian origin and viral vaccines for poultry: current provisions and proposals for future approaches.禽类来源底物的外来因子检测及家禽病毒疫苗:现行规定与未来方法建议
Biologicals. 2010 May;38(3):362-5. doi: 10.1016/j.biologicals.2010.01.010. Epub 2010 Mar 23.
4
Risk reduction in biotherapeutic products.生物治疗产品的风险降低
Curr Opin Drug Discov Devel. 2009 Mar;12(2):296-304.
5
Viral safety and extraneous agents testing for veterinary vaccines: rationale for requirements, the European approach.兽用疫苗的病毒安全性及外源因子检测:要求的基本原理及欧洲的方法
Biologicals. 2010 May;38(3):338-9. doi: 10.1016/j.biologicals.2010.01.008. Epub 2010 Mar 23.
6
Current challenges in viral safety and extraneous agent testing.病毒安全性和外源因子检测中的当前挑战。
Biologicals. 2010 May;38(3):335-7. doi: 10.1016/j.biologicals.2010.01.014. Epub 2010 Mar 24.
7
Comparison of requirements in the European Union and United States of America for pre-clinical viral safety testing of veterinary vaccines.欧盟与美国对兽用疫苗临床前病毒安全性检测要求的比较。
Biologicals. 2010 May;38(3):340-5. doi: 10.1016/j.biologicals.2010.01.001. Epub 2010 Apr 18.
8
Three Rs potential in the development and quality control of immunobiologicals.免疫生物学制品研发与质量控制中的“3R”潜力
ALTEX. 2001;18 Suppl 1:13-47.
9
Use of substances of animal origin in pharmaceutics and compliance with the TSE-risk guideline -- a market survey.药用动物源物质的使用及对传染性海绵状脑病风险指南的遵循情况——一项市场调查
Biologicals. 2005 Mar;33(1):1-7. doi: 10.1016/j.biologicals.2004.10.002.
10
Statistical bases for defining level of assurance.定义保证水平的统计基础。
Dev Biol (Basel). 2006;123:209-16; discussion 217-22.

引用本文的文献

1
Vaccine Production in Africa: A Feasible Business Model for Capacity Building and Sustainable New Vaccine Introduction.非洲的疫苗生产:能力建设与可持续引入新疫苗的可行商业模式
Front Public Health. 2019 Mar 20;7:56. doi: 10.3389/fpubh.2019.00056. eCollection 2019.